Annual report pursuant to Section 13 and 15(d)

Summary of Significant Accounting Policies (Details Narrative)

v3.22.4
Summary of Significant Accounting Policies (Details Narrative) - USD ($)
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Cash and cash equivalents $ 10,867,050 $ 20,581,313
Terms of license Agreement Belgian Volition received an upfront payment of $10.0 million in 2022, and is eligible to receive further milestone payments of (i) $6.5 million upon the first commercial sale by or on behalf of Heska of a POC screening test for Canine Lymphoma & HSA, (ii) $6.5 million upon the first commercial sale by or on behalf of Heska of a POC monitoring test for the same conditions, and (iii) $5.0 million upon the first commercial sale by or on behalf of Heska of a screening or monitoring test for lymphoma in felines  
Initial term for POC 22 years  
Initial term for Central Lab 5 years  
Upfront payment $ 10,000,000.0  
Milestone amount recognized 18,000,000.0  
Amount in excess of FDIC limit 10,079,089 19,753,878
Accumulated other comprehensive loss 227,097 148,326
Research and development expenses 14,600,000 13,000,000.0
Impairment losses 0 0
Accounts receivable 72,609 12,510
Deferred revenue $ 10,000,000.0 $ 12,512,000,000
Warrants And Options [Member]    
Potentially dilutive securities excluded from the computation of EPS 7,787,013 6,323,268
Belgian Deposit Guarantee [Member]    
Deposits/cash in excess of insured limits $ 1,725,981 $ 134,134
Singapore Deposit Insurance [Member]    
Deposits/cash in excess of insured limits 100,601 102,514
UK Deposit Protection Scheme [Member]    
Deposits/cash in excess of insured limits $ 326,631 $ 142,410